The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results